Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLLT1 | Q03111 | 1/20 | 0.67 |
| ▸ | FAAH | O00519 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | SCN4A | P35499 | 1/20 | 0.56 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.56 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.55 |
| ▸ | HTR3A | P46098 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL74244 | 1.00 | MLLT1 (0.67) | MLLT1FAAHKDM4EALDH1A1GAA | |
| SCHEMBL19837645 | 1.00 | MLLT1 (0.67) | MLLT1FAAHKDM4EALDH1A1GAA | |
| SCHEMBL76132 | 0.99 | MLLT1 (0.69) | MLLT1FAAHKDM4EALDH1A1GAA | |
| SCHEMBL75198 | 0.96 | MLLT1 (0.65) | MLLT1FAAHKDM4EALDH1A1GAA | |
| SCHEMBL4018254 | 0.93 | KDM4E (0.62) | MLLT1KDM4EALDH1A1GAAMAPK1 | |
| SCHEMBL30102648 | 0.87 | MAOB (0.60) | MLLT1KDM4EALDH1A1GAAMAPK1 | |
| SCHEMBL19850663 | 0.86 | NPC1 (0.56) | MLLT1KDM4EALDH1A1GAAMAPK1 | |
| SCHEMBL19837662 | 0.86 | NPC1 (0.56) | MLLT1KDM4EALDH1A1GAAMAPK1 | |
| SCHEMBL21490113 | 0.86 | SMYD3 (0.71) | MLLT1KDM4EALDH1A1GAAMAPK1 | |
| SCHEMBL19710676 | 0.86 | SMYD3 (0.71) | MLLT1KDM4EALDH1A1GAAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10383848-B2 | Indole-based therapeutics | CREIGHTON UNIVERSITY (US) | 2019-08-20 | — | — | US | disclosed |
| US-10383848-B2 | Indole-based therapeutics | CREIGHTON UNIVERSITY (US) | 2019-08-20 | — | — | US | disclosed |
| US-20180036283-A1 | INDOLE-BASED THERAPEUTICS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-02-08 | — | — | US | disclosed |
| US-20180036283-A1 | INDOLE-BASED THERAPEUTICS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-02-08 | — | — | US | disclosed |
| US-20180036283-A1 | INDOLE-BASED THERAPEUTICS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-02-08 | — | — | US | disclosed |
| US-8129424-B2 | Indole derivatives as histamine 3 receptor inhibitors for the treatment of cognitive and sleep disorders, obesity and other CNS disorders | ATHERSYS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-20110059966-A1 | INDOLE DERIVATIVES AS HISTAMINE 3 RECEPTOR INHIBITORS FOR THE TREATMENT OF COGNITIVE AND SLEEP DISORDERS, OBESITY AND OTHER CNS DISORDERS | BENNANI YOUSSEF L | 2011-03-10 | — | — | US | disclosed |
| US-7855224-B2 | Indole derivatives as histamine 3 receptor inhibitors for the treatment of cognitive and sleep disorders, obesity and other CNS disorders | ATHERSYS, INC. (US) | 2010-12-21 | — | — | US | disclosed |
| US-20090036446-A1 | Indole derivatives as histamine 3 receptor inhibitors for the treatment of cognitive and sleep disorders, obesity and other CNS disorders | BENNANI YOUSSEF L | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036446-A1 | Indole derivatives as histamine 3 receptor inhibitors for the treatment of cognitive and sleep disorders, obesity and other CNS disorders | HRH3, HCRTR1, HCRTR2 | MLLT1 341/4885FAAH 80/4885KDM4E 447/4885 |
| US-10383848-B2 | Indole-based therapeutics | IDO2, IDO1, INMT | MLLT1 636/4885FAAH 335/4885KDM4E 1991/4885 |
| US-20180036283-A1 | INDOLE-BASED THERAPEUTICS | IDO2, IDO1, INMT | MLLT1 636/4885FAAH 335/4885KDM4E 1991/4885 |
| US-20110059966-A1 | INDOLE DERIVATIVES AS HISTAMINE 3 RECEPTOR INHIBITORS FOR THE TREATMENT OF COGNITIVE AND SLEEP DISORDERS, OBESITY AND OTHER CNS DISORDERS | HRH3, HCRTR1, HCRTR2 | MLLT1 341/4885FAAH 80/4885KDM4E 447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.